These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36139135)
1. Generation and Functional Characterization of PLAP CAR-T Cells against Cervical Cancer Cells. Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135 [TBL] [Abstract][Full Text] [Related]
2. PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells. Li X; Berahovich R; Zhou H; Liu X; Li F; Xu S; Wei Y; Ouaret D; Bodmer W; Wu L; Golubovskaya V Front Biosci (Landmark Ed); 2020 Jun; 25(9):1765-1786. PubMed ID: 32472757 [TBL] [Abstract][Full Text] [Related]
3. Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells. He Y; Li XM; Yin CH; Wu YM J Reprod Immunol; 2020 Jun; 139():103115. PubMed ID: 32199196 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. Li T; Wang J BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954 [TBL] [Abstract][Full Text] [Related]
5. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A Front Immunol; 2021; 12():665970. PubMed ID: 34475869 [TBL] [Abstract][Full Text] [Related]
6. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915 [TBL] [Abstract][Full Text] [Related]
8. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell. Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660 [TBL] [Abstract][Full Text] [Related]
9. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P Front Immunol; 2019; 10():1149. PubMed ID: 31178870 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
11. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926 [TBL] [Abstract][Full Text] [Related]
12. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
13. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells. Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586 [TBL] [Abstract][Full Text] [Related]
14. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
15. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma]. Min JT; Zhang L; Long CR; Fan HL; Li ZZ Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213 [No Abstract] [Full Text] [Related]
16. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity". Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R Front Immunol; 2021; 12():799206. PubMed ID: 34975912 [TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066 [TBL] [Abstract][Full Text] [Related]
18. Effective Targeting of TAG72 Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ Front Immunol; 2018; 9():2268. PubMed ID: 30510550 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
20. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]